ARGX

In the past six months, Argenx SE's stock was impacted by several key events. In July 2026, the company reported strong half-year 2026 results, with second-quarter global product net sales reaching $1.5 billion, a 60% year-over-year and 17% quarter-over-quarter increase, and basic profit per share of $7.58. Also in July 2026, Argenx launched an expanded label for Vyvgart and Vyvgart Hytrulo in the U.S., now covering all gMG serotypes. In August 2026, positive topline results were announced from the Phase 3 ALKIVIA trial of subcutaneous efgartigimod for autoimmune myositis, meeting its primary endpoint. Additionally, Argenx announced its intention to acquire Forte Biosciences for approximately $2.2 billion, adding FB102 to its immunology pipeline. In September 2026, the company held an Extraordinary General Meeting of Shareholders to appoint new non-executive directors, Thomas M. Brakel and Khurem Farooq, and expanded its kidney disease pipeline with a new IgA Nephropathy trial. Analyst sentiment was largely positive, with Jefferies reiterating a 'Buy' rating, Morgan Stanley and Wells Fargo raising their targets, and UBS upgrading the stock to 'Buy', though Deutsche Bank downgraded to 'Hold' following a significant price run-up. Argenx was also added to the IBD 50 growth stock watchlist and has demonstrated 18 consecutive quarters of sales growth.